News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Prozac Scientist Plays Down Cancer Fears (Reuters) Prozac and related antidepressants could in theory pose a cancer threat by blocking the body`s innate ability to kill tumor cells, British scientists said on Tuesday. - Mar 26 3:26 PM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://story.news.yahoo.com/news?tmpl=story&u=/nm/20020326/sc_nm/health_prozac_cancer_dc_6

Posted on: 03/28/2002

Tue Mar 26, 3:26 PM ET

By Ben Hirschler, European Pharmaceuticals Correspondent

LONDON (Reuters) - Prozac and related antidepressants could in theory pose a cancer threat by blocking the body's innate ability to kill tumor cells, British scientists said on Tuesday.

But Professor John Gordon of the University of Birmingham, who led the research, said patients should keep taking their drugs since there was no evidence of any link in practice.

Working in the test-tube, Gordon and others found that the brain's mood-regulating chemical serotonin caused some cancer cells to self-destruct.

Eli Lilly and Co.'s Prozac, Glaxo SmithKline Plc's Paxil and Lundbeck's Celexa all "substantially blocked" this process. The finding reopens controversy about the widespread use of the class of antidepressants called selective serotonin re-uptake inhibitors (SSRIs) that first went on sale in the 1980s.

Millions of people with depression and anxiety have been prescribed the drugs, which have emerged as one of the biggest sellers for the international pharmaceutical industry. They work by stopping serotonin getting into cells.

Gordon's discovery (news - web sites) that serotonin plays a role in killing a type of cancer called Burkitt's lymphoma was published in the online edition of the medical journal Blood.

"We've shown that, in the test-tube, the SSRIs stop the action of the serotonin on the cancer cells. But it's nigh on impossible to extrapolate to what's happening in the body," Gordon told Reuters.

"We must stress the effects shown for SSRIs on cancer cells is indirect and should cause no concern whatsoever to the many millions of people throughout the world who are prescribed this class of antidepressants."

A spokeswoman for Eli Lilly said the results of the study were being misinterpreted to draw a link between SSRIs like Prozac and an increased risk of cancer.

"The study really is based on test-tube results that didn't involve human or animal subjects," said Anne Griffin of Lilly. "There have been thousands of clinical studies of Prozac and its use in some 40 million people, and there's been no link ever found."

A spokesman for Britain's Department of Health said the research was at a very early stage and no increased risk of cancer had been detected.

Rather than being alarmed, Gordon is in fact excited that a new class of anti-cancer drugs may one day be developed that exploit serotonin's ability to kill cancer cells.

"Because we know the mechanism, we are now in a position to develop drug analogs of serotonin that will do the same job but have better pharmacological properties," Gordon said.

His work also provides an intriguing insight into the way that "positive thinking" associated with serotonin levels may play a key part in effective cancer care.

The mechanism by which serotonin can get inside cancer cells and tell them to commit suicide -- a process known as apoptosis -- suggests there is a clear "dialogue" between the brain and the immune system, he said.

Prozac was the first SSRI to reach the market in 1987 but it has since been overtaken by Paxil, also known as Seroxat, which racked up sales last year of 1.86 billion pounds ($2.7 billion).

Drug company officials said they did not believe their pills caused any increase in cancer and questioned whether the high doses used in Gordon's experiments may have affected the results.

"These data are from an in vitro (test tube) study and as such they cannot be extrapolated to a clinical setting with any degree of certainty," said Martin Sutton, a spokesman for GSK.




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740